{"id":810401,"date":"2025-02-07T07:07:39","date_gmt":"2025-02-07T12:07:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/"},"modified":"2025-02-07T07:07:39","modified_gmt":"2025-02-07T12:07:39","slug":"opthea-to-present-at-oppenheimer-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/","title":{"rendered":"Opthea to Present at Oppenheimer Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia and PRINCETON, N.J., Feb.  07, 2025  (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer\u2019s 35<sup>th<\/sup> Annual Healthcare Life Sciences Conference and host one-one-one meetings.<\/p>\n<p align=\"justify\">Details are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Oppenheimer\u2019s 35<sup>th<\/sup> Annual Healthcare Life Sciences Conference<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%;text-align: justify;vertical-align: middle;vertical-align: top\">Date:<\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%;text-align: justify;vertical-align: middle;vertical-align: top\">February 11-12, 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Presentation: \u00a0 <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Tuesday, February 11, 2025, 10:00 AM ET<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Webcast Link:<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"https:\/\/wsw.com\/webcast\/oppenheimer39\/opt\/2588856\" rel=\"nofollow\" target=\"_blank\"><br \/>\n              <u>https:\/\/wsw.com\/webcast\/oppenheimer39\/opt\/2588856<\/u><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: justify;vertical-align: middle;vertical-align: top\">The webcast will also be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at\u00a0<a href=\"http:\/\/ir.opthea.com\/\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/ir.opthea.com\/<\/u><\/a>.<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About Opthea<\/strong>\n      <\/p>\n<p align=\"justify\">Opthea (ASX\/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age\u2010related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide.<\/p>\n<p align=\"justify\">Opthea\u2019s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C\/D \u2018trap\u2019 inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD live fuller and healthier lives.<\/p>\n<p>To learn more, visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nd3OC3SwxQKNUi1Ycv3Zm7nDS4QCvgly_0H7v_pTvsY8A65qhrnAwdLFeMQLmZcPLlXyk4CM7O01-E5R79VfLQ==\" rel=\"nofollow\" target=\"_blank\">www.opthea.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1MrgCSJQUKb-7TLN0ExNso7TSUyr3IXjf4q1ra9lkF8MvEc0ioRWBNPM6iwSqUmn_myNYx86pQ_EM-Opntx0ug==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QEvPElXLS4wbhnqGtKhdwkL9BTumC6-JglRSalmwxNwOAjtQeIvf9HyT5hT0B9BUOiRw97f2Bj6SZgo9dqDk8hPurVAbMJlCVzpvITWYHrc=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">Authorized for release to ASX by Frederic Guerard, PharmD, CEO<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Investor Inquiries<\/strong><\/p>\n<p>PJ Kelleher<br \/>LifeSci Advisors, LLC<br \/>Email:<a href=\"mailto:pkelleher@lifesciadvisors.com\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><br \/>Phone: 617-430-7579<\/td>\n<td style=\"max-width:70%;width:70%;min-width:70%;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Media\u00a0Inquiries<\/strong><\/p>\n<p>Silvana Guerci-Lena<br \/>NorthStream Global Partners<br \/>Email:<a href=\"mailto:silvana@nsgpllc.com\" rel=\"nofollow\" target=\"_blank\">silvana@nsgpllc.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%;text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"max-width:70%;width:70%;min-width:70%;text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Join our email database to receive program updates:\u00a0\u00a0<br \/>Tel: +61 (0) 3 9826 0399, Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=60qAWGB6LJCKwFLBaRl3AxaFa115Q7lNzBHNTy8G3NaGAPL3XMM3Ck6v7W1DT5zxARfaqc19r6p4iw_0GttQCw==\" rel=\"nofollow\" target=\"_blank\"><u>info@opthea.com<\/u><\/a> Web: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nd3OC3SwxQKNUi1Ycv3Zm0RSdEmO4gtjSob-gnjipIxHoJ3DnngwDOizWK8DlmO1UV4NMk5ChkrARvf3BpOXiA==\" rel=\"nofollow\" target=\"_blank\"><u>www.opthea.com<\/u><\/a>\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">Source: Opthea Limited<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTZjMWMyYTUtYTYyZC00NzkyLTlmMTktYjE0YjI4NjYxMDA1LTUwMDEyMTgwNg==\/tiny\/Opthea-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer\u2019s 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows: Oppenheimer\u2019s 35th Annual Healthcare Life Sciences Conference Date: February 11-12, 2025 Presentation: \u00a0 Tuesday, February 11, 2025, 10:00 AM ET Webcast Link: https:\/\/wsw.com\/webcast\/oppenheimer39\/opt\/2588856 The webcast will also be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at\u00a0http:\/\/ir.opthea.com\/. \u00a0 About Opthea Opthea (ASX\/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Opthea to Present at Oppenheimer Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810401","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Opthea to Present at Oppenheimer Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opthea to Present at Oppenheimer Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer\u2019s 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows: Oppenheimer\u2019s 35th Annual Healthcare Life Sciences Conference Date: February 11-12, 2025 Presentation: \u00a0 Tuesday, February 11, 2025, 10:00 AM ET Webcast Link: https:\/\/wsw.com\/webcast\/oppenheimer39\/opt\/2588856 The webcast will also be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at\u00a0http:\/\/ir.opthea.com\/. \u00a0 About Opthea Opthea (ASX\/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat &hellip; Continue reading &quot;Opthea to Present at Oppenheimer Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T12:07:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Opthea to Present at Oppenheimer Healthcare Conference\",\"datePublished\":\"2025-02-07T12:07:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/\",\"name\":\"Opthea to Present at Oppenheimer Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==\",\"datePublished\":\"2025-02-07T12:07:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-oppenheimer-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opthea to Present at Oppenheimer Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opthea to Present at Oppenheimer Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Opthea to Present at Oppenheimer Healthcare Conference - Market Newsdesk","og_description":"MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer\u2019s 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows: Oppenheimer\u2019s 35th Annual Healthcare Life Sciences Conference Date: February 11-12, 2025 Presentation: \u00a0 Tuesday, February 11, 2025, 10:00 AM ET Webcast Link: https:\/\/wsw.com\/webcast\/oppenheimer39\/opt\/2588856 The webcast will also be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at\u00a0http:\/\/ir.opthea.com\/. \u00a0 About Opthea Opthea (ASX\/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat &hellip; Continue reading \"Opthea to Present at Oppenheimer Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-07T12:07:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Opthea to Present at Oppenheimer Healthcare Conference","datePublished":"2025-02-07T12:07:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/","name":"Opthea to Present at Oppenheimer Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==","datePublished":"2025-02-07T12:07:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDY2NCM2NzQwMjU2IzUwMDEyMTgwNg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-oppenheimer-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Opthea to Present at Oppenheimer Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810401"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810401\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}